ORAGENICS, INC. Notes Payable, Current
ORAGENICS, INC. (OGEN) had Notes Payable, Current of $56.13 thousand as of 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:NotesPayableCurrent · last filed 2026-08-13
- 2026-03-31: Notes Payable, Current $56.13K.
- 2025-12-31: Notes Payable, Current $227.35K.
- 2025-09-30: Notes Payable, Current $394.84K.
- 2025-06-30: Notes Payable, Current $3.00M.
| Period end | Notes Payable, Current | Notes Payable, Current as first filed |
|---|---|---|
| 2026-03-31 | $56.13K 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $227.35K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $394.84K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $3.00M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $2.55M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $328.53K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $519.39K 10-Q · filed 2024-11-13 | |
| 2024-03-31 | $126.84K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $312.70K 10-K · filed 2025-03-14 | |
| 2023-09-30 | $493.42K 10-Q · filed 2023-11-09 | |
| 2023-03-31 | $107.89K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $267.64K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $424.92K 10-Q/A · filed 2023-04-14 | |
| 2022-03-31 | $122.17K 10-Q/A · filed 2023-04-14 | |
| 2021-12-31 | $303.42K 10-K · filed 2023-04-17 | |
| 2021-09-30 | $482.26K 10-Q · filed 2021-11-15 | |
| 2021-03-31 | $114.88K 10-Q · filed 2021-05-03 | |
| 2020-12-31 | $228.23K 10-K/A · filed 2022-07-29 | |
| 2020-09-30 | $472.15K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $132.09K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $70.85K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $228.23K 10-Q · filed 2021-05-03 | $143.86K 10-K · filed 2020-03-04 |
| 2018-12-31 | $124.21K 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |